je.st
news
UPDATE 1-Infection worries prompt regulatory reviews of Gilead leukaemia drug
2016-03-12 05:33:35| Biotech - Topix.net
European and U.S. regulators are reviewing the safety of Gilead Sciences' leukaemia drug Zydelig due to concerns over serious adverse events, including deaths. The actions were prompted by an increased rate of harmful events, mostly due to infections, seen in three clinical trials that tested the drug in combination with other cancer medicines, the European Medicines Agency said on Friday.
Tags: reviews
update
drug
regulatory
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|
|||